Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, Wermke M, Bornhäuser M, Ritter M, Neubauer A, Ehninger G, Illmer T.

Blood. 2002 Jun 15;99(12):4326-35.

2.
3.

FLT3 in human hematologic malignancies.

Kiyoi H, Naoe T.

Leuk Lymphoma. 2002 Aug;43(8):1541-7. Review.

PMID:
12400596
4.

Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review.

Beitinjaneh A, Jang S, Roukoz H, Majhail NS.

Leuk Res. 2010 Jul;34(7):831-6. doi: 10.1016/j.leukres.2010.01.001. Epub 2010 Jan 21. Review.

PMID:
20096459
5.

Role of FLT3 in leukemia.

Gilliland DG, Griffin JD.

Curr Opin Hematol. 2002 Jul;9(4):274-81. Review.

PMID:
12042700
6.

Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia.

Kottaridis PD, Gale RE, Linch DC.

Leuk Lymphoma. 2003 Jun;44(6):905-13. Review.

PMID:
12854887
7.

FLT3 and its role in the pathogenesis of acute myeloid leukaemia.

Reilly JT.

Leuk Lymphoma. 2003 Jan;44(1):1-7. Review.

PMID:
12691136
8.

Flt3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications.

Voutsadakis IA.

Med Oncol. 2003;20(4):311-24. Review.

PMID:
14716027
9.

FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia.

Schnittger S, Schoch C, Kern W, Hiddemann W, Haferlach T.

Acta Haematol. 2004;112(1-2):68-78. Review.

PMID:
15179006
10.

Prognostic factors in AML in relation to (ab)normal karyotype.

Stone RM.

Best Pract Res Clin Haematol. 2009 Dec;22(4):523-8. doi: 10.1016/j.beha.2009.07.003. Review.

PMID:
19959103
11.

FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia.

Leung AY, Man CH, Kwong YL.

Leukemia. 2013 Feb;27(2):260-8. doi: 10.1038/leu.2012.195. Epub 2012 Jul 16. Review.

PMID:
22797419
12.

Normal and oncogenic FLT3.

Naoe T, Kiyoi H.

Cell Mol Life Sci. 2004 Dec;61(23):2932-8. Review.

PMID:
15583855
13.

High cytogenetic or molecular genetic risk acute myeloid leukemia.

Estey E.

Hematology Am Soc Hematol Educ Program. 2010;2010:474-80. doi: 10.1182/asheducation-2010.1.474. Review.

PMID:
21239839
14.

FLT3 inhibitors in acute myeloid leukemia.

el-Shami K, Stone RM, Smith BD.

Expert Rev Hematol. 2008 Dec;1(2):153-60. doi: 10.1586/17474086.1.2.153. Review.

PMID:
21082920
15.

Acute myelogenous leukemia with t(6;9)(p23;q34) and marrow basophilia: an overview.

Chi Y, Lindgren V, Quigley S, Gaitonde S.

Arch Pathol Lab Med. 2008 Nov;132(11):1835-7. doi: 10.1043/1543-2165-132.11.1835. Review.

PMID:
18976025
16.

From kinases to cancer: leakiness, loss of autoinhibition and leukemia.

Reindl C, Spiekermann K.

Cell Cycle. 2006 Mar;5(6):599-602. Epub 2006 Mar 15. Review.

PMID:
16582613
17.

Gene expression profiling in acute myeloid leukaemia.

de Jonge HJ, Huls G, de Bont ES.

Neth J Med. 2011 Apr;69(4):167-76. Review.

18.

Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.

Shabbir M, Stuart R.

Expert Opin Investig Drugs. 2010 Mar;19(3):427-36. doi: 10.1517/13543781003598862. Review.

PMID:
20141349
19.

Differential signaling of Flt3 activating mutations in acute myeloid leukemia: a working model.

Chan PM.

Protein Cell. 2011 Feb;2(2):108-15. doi: 10.1007/s13238-011-1020-7. Epub 2011 Feb 25. Review.

20.

FLT3: ITDoes matter in leukemia.

Levis M, Small D.

Leukemia. 2003 Sep;17(9):1738-52. Review.

PMID:
12970773
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk